Preliminary Human Trials of F230 Tablets

NCT06899815 · tracked via the Priya Life Science China tracker

Sponsor

Beijing Continent Pharmaceutical Co, Ltd

Phase

Phase 1

Started

2025-05-15

Last updated

2026-03-11

Condition(s) studied

Pulmonary Hypertension

Investigational drug(s) / intervention(s)

F230 tablets

F230 tablets: SAD： A1: F230 tablets 3mg;A2: F230 tablets 6mg;A3: F230 tablets 12mg;A4: F230 tablets 20mg;A5: F230 tablets 30mg;A6: F230 tablets 40mg . MAD： B1: F230 tablets 10mg; B2: F230 tablets 20mg; B3: F230 tablets 30mg; Studies on the effects of food on drugs:Group K-C: The first cycle was fasting administration, and the second cycle was postprandial administration;C-K:The first cycle was given after meals, and the second cycle was given on an empty stomach.

Study summary

F230 is a new Class 1 chemical drug jointly developed by Beijing Contini Pharmaceutical Co., Ltd. for the treatment of pulmonary hypertension (Notification number: 2024LP01242, 2024LP01243). The in vitro activity and in vivo toxicology tests of F230, the lead compound for the treatment of PAH developed by Beijing Contini Pharmaceutical Co., LTD., showed that F230 had the same in vitro activity as the endothelin antagonist on the market. The pharmacodynamics of F230 in rats with nephrogenic hypertension induced by Sunitinib showed that F230 could reduce proteinuria and improve renal index.It is expected to bring higher treatment and survival benefits to the corresponding patients. According to the spirit of NMPA new drug approval, on the basis of the completion of preclinical studies of this drug, the safety, tolerability and pharmacokinetic characteristics of single administration and multiple administration of this drug in healthy volunteers should be investigated first, and the influence of food on the pharmacokinetic characteristics of F230 in humans should be investigated, so as to recommend a safe and effective administration regimen for phase II clinical trials.

Eligibility

Sex

ALL

Min age

18 Years

Max age

45 Years

Healthy volunteers

Accepted

Inclusion Criteria: Volunteers must meet all of the following criteria to be selected: 1. Healthy volunteers, half male and half female, should be replaced by volunteers of the same sex; 2. Age: 18 \~ 45 years old; 3. Weight: male ≥50kg, female ≥45kg, 19≤BMI≤26 (BMI= weight (kg)/height 2 (m2)); 4. Pass the comprehensive health examination: vital signs, physical examination, blood urine routine, blood pregnancy, blood glucose, blood lipid, blood electrolyte, hepatitis B surface antigen, liver and kidney function, hepatitis C, HIV and syphilis antibody test, 12-lead electrocardiogram, nicotine, urine drug screening, alcohol breath test, abdominal B-ultrasound, chest X-ray examination, etc., no abnormalities or abnormalities have no clinical significance; 5. Before participating in the study, have a detailed understanding of the nature, significance, possible benefits, possible inconveniences and potential dangers of the trial, and voluntarily participate in this clinical trial, can communicate well with the investigators, comply with the requirements of the entire study, and have the ability to understand and sign the written informed consent. Exclusion Criteria: * Volunteers who meet one of the following conditions are not eligible for this study: 1. Participants in any other clinical trial within three months prior to the trial; 2. Serum ALT \> upper limit of normal (ULN), AST \> Upper limit of normal (ULN), TBil \> upper limit of normal (ULN); 3. (Inquiry) Are there any underlying liver diseases, such as chronic hepatitis B, chronic hepatitis C, alcoholic liver disease, moderate to severe non-alcoholic fatty liver disease, liver cirrhosis, etc.; 4. (Consultation) Have any disease that may affect the safety of the trial or the process of the drug in vivo, including but not limited to: Heart, liver, kidney, endocrine, digestive, immune, respiratory, nervous or psychiatric systems, or other pre-existing or existing diseases of the above systems \[especially cardiovascular disease including those at risk for cardiovascular disease, any gastrointestinal disease that interferes with drug absorption (e.g. symptoms of irritable bowel syndrome, history of inflammatory bowel disease), active pathological bleeding (e.g. peptic ulcer), urticaria, epilepsy, epilepsy, etc. Sensitive rhinitis, eczematous dermatitis, asthma, active pulmonary tuberculosis, etc. 5. (Consultation) Allergy: If there is a history of drug, food allergy or skin allergy; 6. (Interview) Any drug that inhibits or induces liver metabolism of the drug in the 28 days prior to the use of the study drug (common liver enzyme inducers: barbiturates such as phenobarbital, carbamazepine, aminomide, grofulvin, methylaminopropyl, phenytoin, Grumette, rifampin, dexamethasone; Common liver enzyme inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol, isoniazid, sulfonamide);

Primary outcome measure(s)

Single dose:PK parameters: Cmax — Within 48 hours of dosing
Blood PK parameters
Single dose:PK parameters: Tmax — Within 48 hours of dosing
Blood PK parameters
Single dose:PK parameters: AUC0-t — Within 48 hours of dosing
Blood PK parameters
Single dose:PK parameters: AUC0-∞ — Within 48 hours of dosing
Blood PK parameters
Single dose:PK parameters: t1/2 — Within 48 hours of dosing
Blood PK parameters
Single dose:PK parameters: λz — Within 48 hours of dosing
Blood PK parameters
Single dose:PK parameters: Vz/F — Within 48 hours of dosing
Blood PK parameters
Single dose:PK parameters: CL/F — Within 48 hours of dosing
Blood PK parameters
Single dose:PK parameters: AUC_%Extrap — Within 48 hours of dosing
Blood PK parameters
Single dose:PK parameters: MRT — Within 48 hours of dosing
Blood PK parameters
Single dose:PK parameters: Ae_u (t1-t2) — Within 48 hours of dosing
Urine PK parameters
Single dose:PK parameters: Ae_u (0-t) — Within 48 hours of dosing
Urine PK parameters
Single dose:PK parameters: Rate_u (max) — Within 48 hours of dosing
Urine PK parameters
Single dose:PK parameters:Fe_u (0-t) — Within 48 hours of dosing
Urine PK parameters
Multiple administration: PK parameters:Cmax,ss — Within 48 hours of dosing
Blood PK parameters
Multiple administration: PK parameters:Tmax,ss — Within 48 hours of dosing
Blood PK parameters
Multiple administration: PK parameters: AUC0-τ,ss — Within 48 hours of dosing
Blood PK parameters
Multiple administration: PK parameters: AUC0-t — Within 48 hours of dosing
Blood PK parameters
Multiple administration: PK parameters: AUC0-∞ — Within 48 hours of dosing
Blood PK parameters
Multiple administration: PK parameters:Cmin,ss — Within 48 hours of dosing
Blood PK parameters
Multiple administration: PK parameters: Cav,ss — Within 48 hours of dosing
Blood PK parameters
Multiple administration: PK parameters: t1/2 — Within 48 hours of dosing
Blood PK parameters
Multiple administration: PK parameters: λz — Within 48 hours of dosing
Blood PK parameters
Multiple administration: PK parameters: CLss/F — Within 48 hours of dosing
Blood PK parameters
Multiple administration: PK parameters: AUC_%Extrap — Within 48 hours of dosing
Blood PK parameters
Multiple administration: PK parameters: MRT — Within 48 hours of dosing
Blood PK parameters
Multiple administration: PK parameters: DF — Within 48 hours of dosing
Blood PK parameters
Multiple administration: PK parameters: Rac — Within 48 hours of dosing
Blood PK parameters
Effects of food on single pharmacokinetic parameters: Cmax — Within 48 hours of dosing
Blood PK parameters
Effects of food on single pharmacokinetic parameters: Tmax — Within 48 hours of dosing
Blood PK parameters
Effects of food on single pharmacokinetic parameters: AUC — Within 48 hours of dosing
Blood PK parameters

Trial sites (1)

Facility	City	Region	Status
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology	Hubei	Wuhan	Recruiting

More Beijing Continent Pharmaceutical Co, Ltd. trials in China

A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B. Starting soon

A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency Recruiting

F573 for Injection for the Treatment of Liver Injury/Failure Recruiting

Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia Recruiting

Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis Recruiting

Other trials for the same condition

A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease Recruiting

Inhaled Nitric Oxide for the Treatment of Neonatal Hypoxic Respiratory Failure With Pulmonary Hypertension Recruiting

Insights Into Pediatric Pulmonary Hypertension: A Real-World Registry of Epidemiology and Outcomes Recruiting

Study on the Treatment of Nonthrombotic Obstructive Pulmonary Hypertension Recruiting

Real-World Study of PADN for the Treatment of PAH Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06899815 on ClinicalTrials.gov ↗ ← All trials in China